Parveen Garg, MD
Cardiovascular Disease · Los Angeles, CANPI 1124284716
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,312 with a category attached, or 86.5%. E.r. Squibb & Sons, L.L.C. accounts for 86.5% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $2,000, more than ten times the $122 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 8 payments — averaging $288.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Regeneron$139
- GE HealthCare$122
- Novo Nordisk$31
- Regeneron Healthcare Solutions, Inc.$19
Across 36 payments — averaging $18,713 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$555K
- Eli Lilly$119K
What the payments were for
- Speaking & faculty fees$2,00087%
- Food & beverage$29313%
- Education$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,000 |
| Regeneron | 2 | $139 |
| GE HealthCare | 3 | $122 |
| Novo Nordisk | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,312 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 70 | $73,510 |
| JardianceEmpagliflozin | 39 | $42,735 |
| VascepaIcosapent Ethyl | 63 | $36,149 |
| EntrestoSacubitril/Valsartan | 28 | $30,650 |
| Praluent PenAlirocumab | 25 | $17,701 |
| XareltoRivaroxaban | 15 | $17,631 |
| EliquisApixaban | 11 | $17,527 |
| Icosapent Ethyl | 30 | $8,159 |
| Rosuvastatin Calcium | 172 | $3,828 |
| Ezetimibe | 88 | $3,521 |
| Colchicine | 13 | $2,283 |
| Metoprolol Succinate | 51 | $1,087 |
| Atorvastatin Calcium | 108 | $1,086 |
| Chlorthalidone | 36 | $583 |
| Amlodipine Besylate | 64 | $358 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.